HIF-1α ||| S:0 E:6 ||| FW
/ ||| S:6 E:7 ||| FW
MDR1  ||| S:7 E:12 ||| FW
pathway  ||| S:12 E:20 ||| FW
confers  ||| S:20 E:28 ||| FW
chemoresistance  ||| S:28 E:44 ||| FW
to  ||| S:44 E:47 ||| TO
cisplatin  ||| S:47 E:57 ||| VB
in  ||| S:57 E:60 ||| IN
bladder  ||| S:60 E:68 ||| JJ
cancer  ||| S:68 E:75 ||| NN
Bladder  ||| S:75 E:83 ||| NNP
cancer  ||| S:83 E:90 ||| NN
( ||| S:90 E:91 ||| -LRB-
BCa ||| S:91 E:94 ||| NNP
)  ||| S:94 E:96 ||| -RRB-
is  ||| S:96 E:99 ||| VBZ
the  ||| S:99 E:103 ||| DT
9th  ||| S:103 E:107 ||| CD
most  ||| S:107 E:112 ||| RBS
common  ||| S:112 E:119 ||| JJ
malignant  ||| S:119 E:129 ||| JJ
tumor  ||| S:129 E:135 ||| NN
and  ||| S:135 E:139 ||| CC
the  ||| S:139 E:143 ||| DT
13th  ||| S:143 E:148 ||| JJ
leading  ||| S:148 E:156 ||| JJ
cause  ||| S:156 E:162 ||| NN
of  ||| S:162 E:165 ||| IN
death  ||| S:165 E:171 ||| NN
due  ||| S:171 E:175 ||| JJ
to  ||| S:175 E:178 ||| TO
cancer ||| S:178 E:184 ||| NN
.  ||| S:184 E:186 ||| .
The  ||| S:186 E:190 ||| DT
development  ||| S:190 E:202 ||| NN
of  ||| S:202 E:205 ||| IN
surgery  ||| S:205 E:213 ||| NN
and  ||| S:213 E:217 ||| CC
target  ||| S:217 E:224 ||| NN
drugs  ||| S:224 E:230 ||| NNS
bring  ||| S:230 E:236 ||| VBP
new  ||| S:236 E:240 ||| JJ
challenges  ||| S:240 E:251 ||| NNS
for  ||| S:251 E:255 ||| IN
the  ||| S:255 E:259 ||| DT
traditional  ||| S:259 E:271 ||| JJ
concept  ||| S:271 E:279 ||| NN
for  ||| S:279 E:283 ||| IN
BCa  ||| S:283 E:287 ||| JJ
therapy ||| S:287 E:294 ||| NN
,  ||| S:294 E:296 ||| ,
and  ||| S:296 E:300 ||| CC
chemotherapy  ||| S:300 E:313 ||| NN
is  ||| S:313 E:316 ||| VBZ
still  ||| S:316 E:322 ||| RB
the  ||| S:322 E:326 ||| DT
final  ||| S:326 E:332 ||| JJ
option  ||| S:332 E:339 ||| NN
for  ||| S:339 E:343 ||| IN
many  ||| S:343 E:348 ||| JJ
BCa  ||| S:348 E:352 ||| JJ
patients ||| S:352 E:360 ||| NNS
,  ||| S:360 E:362 ||| ,
and  ||| S:362 E:366 ||| CC
cisplatin-containing  ||| S:366 E:387 ||| JJ
regimen  ||| S:387 E:395 ||| NNS
the  ||| S:395 E:399 ||| DT
most  ||| S:399 E:404 ||| RBS
effective  ||| S:404 E:414 ||| JJ
one ||| S:414 E:417 ||| NN
.  ||| S:417 E:419 ||| .
However ||| S:419 E:426 ||| RB
,  ||| S:426 E:428 ||| ,
the  ||| S:428 E:432 ||| DT
ubiquitous  ||| S:432 E:443 ||| JJ
application  ||| S:443 E:455 ||| NN
of  ||| S:455 E:458 ||| IN
cisplatin-containing  ||| S:458 E:479 ||| JJ
regimen  ||| S:479 E:487 ||| NN
in  ||| S:487 E:490 ||| IN
BCa  ||| S:490 E:494 ||| JJ
results  ||| S:494 E:502 ||| NNS
in  ||| S:502 E:505 ||| IN
the  ||| S:505 E:509 ||| DT
cisplatin-resistance ||| S:509 E:529 ||| JJ
,  ||| S:529 E:531 ||| ,
in  ||| S:531 E:534 ||| IN
addition ||| S:534 E:542 ||| NN
,  ||| S:542 E:544 ||| ,
the  ||| S:544 E:548 ||| DT
cisplatin‑resistant  ||| S:548 E:568 ||| NNP
BCa  ||| S:568 E:572 ||| NNP
manifests  ||| S:572 E:582 ||| VBD
enhanced  ||| S:582 E:591 ||| VBN
malignant  ||| S:591 E:601 ||| JJ
behavior ||| S:601 E:609 ||| NN
,  ||| S:609 E:611 ||| ,
the  ||| S:611 E:615 ||| DT
mechanism  ||| S:615 E:625 ||| NN
of  ||| S:625 E:628 ||| IN
which  ||| S:628 E:634 ||| WDT
is  ||| S:634 E:637 ||| VBZ
unclear ||| S:637 E:644 ||| JJ
.  ||| S:644 E:646 ||| .
In  ||| S:646 E:649 ||| IN
the  ||| S:649 E:653 ||| DT
present  ||| S:653 E:661 ||| JJ
study ||| S:661 E:666 ||| NN
,  ||| S:666 E:668 ||| ,
we  ||| S:668 E:671 ||| PRP
used  ||| S:671 E:676 ||| VBD
BCa  ||| S:676 E:680 ||| JJ
cell  ||| S:680 E:685 ||| NN
lines  ||| S:685 E:691 ||| NNS
to  ||| S:691 E:694 ||| TO
to  ||| S:694 E:697 ||| TO
clarify  ||| S:697 E:705 ||| VB
this  ||| S:705 E:710 ||| DT
point ||| S:710 E:715 ||| NN
.  ||| S:715 E:717 ||| .
BCa  ||| S:717 E:721 ||| JJ
cell  ||| S:721 E:726 ||| NN
lines  ||| S:726 E:732 ||| NNS
T24 ||| S:732 E:735 ||| NNP
/ ||| S:735 E:736 ||| NNP
J82  ||| S:736 E:740 ||| NNP
were  ||| S:740 E:745 ||| VBD
pretreated  ||| S:745 E:756 ||| VBN
with  ||| S:756 E:761 ||| IN
cisplatin  ||| S:761 E:771 ||| CD
> ||| S:771 E:772 ||| CD
3 months  ||| S:772 E:781 ||| CD
to  ||| S:781 E:784 ||| TO
construct  ||| S:784 E:794 ||| VB
stable  ||| S:794 E:801 ||| JJ
cisplatin-resistant  ||| S:801 E:821 ||| JJ
cell  ||| S:821 E:826 ||| NN
lines  ||| S:826 E:832 ||| NNS
( ||| S:832 E:833 ||| -LRB-
tagged  ||| S:833 E:840 ||| FW
T24Cis-R  ||| S:840 E:849 ||| FW
and  ||| S:849 E:853 ||| CC
J82Cis-R ||| S:853 E:861 ||| CD
) ||| S:861 E:862 ||| -RRB-
,  ||| S:862 E:864 ||| ,
which  ||| S:864 E:870 ||| WDT
manifested  ||| S:870 E:881 ||| VBP
as  ||| S:881 E:884 ||| RB
enhanced  ||| S:884 E:893 ||| JJ
capacity  ||| S:893 E:902 ||| NN
of  ||| S:902 E:905 ||| IN
proliferation  ||| S:905 E:919 ||| NN
and  ||| S:919 E:923 ||| CC
malignant  ||| S:923 E:933 ||| JJ
behavior  ||| S:933 E:942 ||| NN
in vivo  ||| S:942 E:950 ||| NN
and  ||| S:950 E:954 ||| CC
in vitro ||| S:954 E:962 ||| NNP
,  ||| S:962 E:964 ||| ,
accompanied  ||| S:964 E:976 ||| VBN
by  ||| S:976 E:979 ||| IN
cisplatin ||| S:979 E:988 ||| NN
,  ||| S:988 E:990 ||| ,
and  ||| S:990 E:994 ||| CC
even  ||| S:994 E:999 ||| RB
doxorubicin  ||| S:999 E:1011 ||| JJ
resistance ||| S:1011 E:1021 ||| NN
.  ||| S:1021 E:1023 ||| .
The  ||| S:1023 E:1027 ||| DT
following  ||| S:1027 E:1037 ||| JJ
mechanism  ||| S:1037 E:1047 ||| NN
dissection  ||| S:1047 E:1058 ||| VBZ
revealed  ||| S:1058 E:1067 ||| VBN
that  ||| S:1067 E:1072 ||| IN
prolonged  ||| S:1072 E:1082 ||| JJ
treatment  ||| S:1082 E:1092 ||| NN
time  ||| S:1092 E:1097 ||| NN
of  ||| S:1097 E:1100 ||| IN
T24 ||| S:1100 E:1103 ||| CD
/ ||| S:1103 E:1104 ||| CD
J82  ||| S:1104 E:1108 ||| CD
cells  ||| S:1108 E:1114 ||| NNS
led  ||| S:1114 E:1118 ||| VBN
to  ||| S:1118 E:1121 ||| TO
elevated  ||| S:1121 E:1130 ||| VB
expression  ||| S:1130 E:1141 ||| NN
of  ||| S:1141 E:1144 ||| IN
HIF-1α ||| S:1144 E:1150 ||| NNP
,  ||| S:1150 E:1152 ||| ,
which  ||| S:1152 E:1158 ||| WDT
targeted  ||| S:1158 E:1167 ||| VBD
the  ||| S:1167 E:1171 ||| DT
increased  ||| S:1171 E:1181 ||| JJ
expression  ||| S:1181 E:1192 ||| NN
of  ||| S:1192 E:1195 ||| IN
MDR1  ||| S:1195 E:1200 ||| CD
on  ||| S:1200 E:1203 ||| IN
the  ||| S:1203 E:1207 ||| DT
one  ||| S:1207 E:1211 ||| CD
hand ||| S:1211 E:1215 ||| NN
,  ||| S:1215 E:1217 ||| ,
and  ||| S:1217 E:1221 ||| CC
contributed  ||| S:1221 E:1233 ||| VBD
to  ||| S:1233 E:1236 ||| TO
BCa  ||| S:1236 E:1240 ||| JJ
cell  ||| S:1240 E:1245 ||| NN
proliferation ||| S:1245 E:1258 ||| NN
,  ||| S:1258 E:1260 ||| ,
migration ||| S:1260 E:1269 ||| CD
/ ||| S:1269 E:1270 ||| CD
invasion  ||| S:1270 E:1279 ||| NN
on  ||| S:1279 E:1282 ||| IN
the  ||| S:1282 E:1286 ||| DT
other  ||| S:1286 E:1292 ||| JJ
hand ||| S:1292 E:1296 ||| NN
.  ||| S:1296 E:1298 ||| .
Finally ||| S:1298 E:1305 ||| RB
,  ||| S:1305 E:1307 ||| ,
IHC  ||| S:1307 E:1311 ||| NNP
staining  ||| S:1311 E:1320 ||| NN
of  ||| S:1320 E:1323 ||| IN
human  ||| S:1323 E:1329 ||| JJ
BCa  ||| S:1329 E:1333 ||| JJ
tissue  ||| S:1333 E:1340 ||| NN
supported  ||| S:1340 E:1350 ||| VBD
our  ||| S:1350 E:1354 ||| PRP$
conclusion  ||| S:1354 E:1365 ||| NN
that  ||| S:1365 E:1370 ||| IN
the  ||| S:1370 E:1374 ||| DT
expression  ||| S:1374 E:1385 ||| NN
of  ||| S:1385 E:1388 ||| IN
HIF-1α  ||| S:1388 E:1395 ||| NNP
and  ||| S:1395 E:1399 ||| CC
MDR1  ||| S:1399 E:1404 ||| NNP
was  ||| S:1404 E:1408 ||| VBD
higher  ||| S:1408 E:1415 ||| JJR
in  ||| S:1415 E:1418 ||| IN
chemoresistant  ||| S:1418 E:1433 ||| FW
tissue  ||| S:1433 E:1440 ||| FW
vs.  ||| S:1440 E:1444 ||| FW
chemosensitive  ||| S:1444 E:1459 ||| FW
tissue ||| S:1459 E:1465 ||| FW
.  ||| S:1465 E:1467 ||| .
Our  ||| S:1467 E:1471 ||| PRP$
results  ||| S:1471 E:1479 ||| NNS
provided  ||| S:1479 E:1488 ||| VBD
a  ||| S:1488 E:1490 ||| DT
new  ||| S:1490 E:1494 ||| JJ
view  ||| S:1494 E:1499 ||| NN
of  ||| S:1499 E:1502 ||| IN
HIF-1α  ||| S:1502 E:1509 ||| CD
in  ||| S:1509 E:1512 ||| IN
chemotherapy ||| S:1512 E:1524 ||| NN
.  ||| S:1524 E:1526 ||| .
